“Chemical Analogues” of HLA-DM Can Induce a Peptide-receptive State in HLA-DR Molecules*

We had recently identified small molecular compounds that are able to accelerate the ligand exchange reactions of HLA-DR molecules. Here we show that this acceleration is due to the induction of a “peptide-receptive” state. Dissociation experiments of soluble HLA-DR2·CLIP (class II-associated invariant chain peptide) complex and peptide-binding studies with “nonreceptive” empty HLA-DR1 and -DR2 molecules revealed that the presence of a small phenolic compound carrying an H-bond donor group (–OH) results in the drastic increase of both off- and on-rates. The rate-limiting step for ligand exchange, the transition of the major histocompatibility complex molecule from a nonreceptive into the receptive state, is normally mediated by interaction with the chaperone HLA-DM. In this respect, the effect of small molecules resembles that of the natural catalyst, except that they are still active at neutral pH. These “chemical analogues” of HLA-DM can therefore modulate the response of CD4+ T cells by editing the antigen composition of surface-bound class II major histocompatibility complex on living antigen-presenting cells.

[1]  P. Cresswell,et al.  Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding , 1990, Nature.

[2]  R. Doebele,et al.  Determination of the HLA-DM interaction site on HLA-DR molecules. , 2000, Immunity.

[3]  P. Cresswell,et al.  HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides , 1992, Nature.

[4]  D. Wiley,et al.  MHC class II function preserved by low-affinity peptide interactions preceding stable binding , 1994, Nature.

[5]  O. Bakke,et al.  MHC class II-associated invariant chain contains a sorting signal for endosomal compartments , 1990, Cell.

[6]  D. Zaller,et al.  The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation. , 1998, Immunity.

[7]  D. Wiley,et al.  The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide , 1992, Cell.

[8]  L. Stern,et al.  A three-step kinetic mechanism for peptide binding to MHC class II proteins. , 2000, Biochemistry.

[9]  L. Stern,et al.  The kinetic basis of peptide exchange catalysis by HLA-DM , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  G. Hämmerling,et al.  Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  G. Hämmerling,et al.  Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  H. Mcconnell,et al.  Peptide Binding to Active Class II MHC Protein on the Cell Surface1 , 2001, The Journal of Immunology.

[13]  P. Cresswell,et al.  HLA-DM Interactions with Intermediates in HLA-DR Maturation and a Role for HLA-DM in Stabilizing Empty HLA-DR Molecules , 1996, The Journal of experimental medicine.

[14]  L Gauthier,et al.  Expression and crystallization of the complex of HLA-DR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic protein. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Woody,et al.  Human T-cell clones recognize chemically synthesized peptides of influenza haemagglutinin , 1982, Nature.

[16]  A. Sant,et al.  Cutting edge: a single, essential hydrogen bond controls the stability of peptide-MHC class II complexes. , 1999, Journal of immunology.

[17]  J. Strominger,et al.  A pH-sensitive histidine residue as control element for ligand release from HLA-DR molecules , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Woods,et al.  Induction of autoimmune arthritis in HLA-DR4 (DRB1*0401) transgenic mice by immunization with human and bovine type II collagen. , 1998, Journal of immunology.

[19]  G. Hämmerling,et al.  HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. , 1997, Immunity.

[20]  Lawrence Steinman,et al.  T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis , 1986, Nature.

[21]  S. Sadegh-Nasseri,et al.  Stable peptide binding to MHC class II molecule is rapid and is determined by a receptive conformation shaped by prior association with low affinity peptides. , 1999, Journal of immunology.

[22]  O. Rötzschke,et al.  Small-molecular compounds enhance the loading of APC with encephalitogenic MBP protein. , 2003, Journal of autoimmunity.

[23]  R. Sékaly,et al.  Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum. , 1996, The EMBO journal.

[24]  B. Evavold,et al.  Enhanced Dissociation of HLA-DR-Bound Peptides in the Presence of HLA-DM , 1996, Science.

[25]  D. Zaller,et al.  Mediation by HLA-DM of dissociation of peptides from HLA-DR , 1995, Nature.

[26]  L. Stern,et al.  Sodium dodecyl sulfate stability of HLA-DR1 complexes correlates with burial of hydrophobic residues in pocket 1. , 1999, Journal of immunology.

[27]  C. Brosnan,et al.  Induction and Suppression of an Autoimmune Disease by Oligomerized T Cell Epitopes , 2000, The Journal of experimental medicine.

[28]  J. Strominger,et al.  Ligand Exchange of Major Histocompatibility Complex Class II Proteins Is Triggered by H-bond Donor Groups of Small Molecules* , 2002, The Journal of Biological Chemistry.

[29]  M. Vrljic,et al.  Formation of a highly peptide-receptive state of class II MHC. , 1998, Immunity.

[30]  G. Nolan,et al.  Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides. , 2003, Immunity.

[31]  D. Zaller,et al.  Identification of the Lateral Interaction Surfaces of Human Histocompatibility Leukocyte Antigen (HLA)-DM with HLA-DR1 by Formation of Tethered Complexes That Present Enhanced HLA-DM Catalysis , 2002, Journal of Experimental Medicine.